Suchergebnisse - "Usmani, Saad Z"

PubPharm (8)

1

Post-protocol therapy and informative censoring in the CANDOR study - Authors' reply

enthalten in: The Lancet. Oncology | 2022

von Usmani, S. | Li, C. | Obreja, M. | +1

CommentOn: Lancet Oncol. 2022 Jan;23(1):65-76. - PMID 34871550

2

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR) : updated outcomes from a randomised, multicentre, open-label, phase 3 study

enthalten in: The Lancet. Oncology | 2022

von Usmani, S. | Quach, H. | Mateos, M. | +15

CommentIn: Lancet Oncol. 2022 Mar;23(3):e97. - PMID 35240098

3

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA) : overall survival results from a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Facon, T. | Kumar, S. | Plesner, T. | +26

4

Treatment of relapsed and refractory multiple myeloma : recommendations from the International Myeloma Working Group

enthalten in: The Lancet. Oncology | 2021

von Moreau, P. | Kumar, S. | San Miguel, J. | +67

5

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2) : a two-arm, randomised, open-label, phase 2 study

enthalten in: The Lancet. Oncology | 2020

von Lonial, S. | Lee, H. | Badros, A. | +35

6

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders : a consensus statement by the International Myeloma Working Group

enthalten in: The Lancet. Oncology | 2017

von Cavo, M. | Terpos, E. | Nanni, C. | +25

7

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

enthalten in: The Lancet. Oncology | 2016

von Kumar, S. | Paiva, B. | Anderson, K. | +37

8

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

enthalten in: The Lancet. Oncology | 2014

von Rajkumar, S. | Dimopoulos, M. | Palumbo, A. | +31

1
[1]